Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13236238 | 0.87 | MAPT (0.39) | PTGDR2POLBNOS1CYP2C19ALDH1A1 | |
| SCHEMBL2945205 | 0.84 | GABRP (0.38) | CYP1A2CYP2C19ALDH1A1CYP19A1KMT2A | |
| SCHEMBL13817752 | 0.83 | MAPT (0.36) | PTGDR2POLBNOS1CYP2C19ALDH1A1 | |
| SCHEMBL2944286 | 0.80 | PTGDR2 (0.48) | PTGDR2CYP1A2POLBNOS1CYP2C19 | |
| SCHEMBL5959155 | 0.78 | POLB (0.39) | PTGDR2CYP1A2POLBNOS1CYP2C19 | |
| SCHEMBL2942332 | 0.73 | PTGDR2 (0.52) | PTGDR2 | |
| SCHEMBL2947947 | 0.71 | CYP1A2 (0.44) | PTGDR2CYP1A2POLBCYP2C19LTA4H | |
| SCHEMBL2950073 | 0.71 | CYP1A2 (0.44) | PTGDR2CYP1A2POLBCYP2C19LTA4H | |
| SCHEMBL1923032 | 0.70 | PTGDR2 (0.39) | PTGDR2POLBNOS1ALDH1A1KMT2A | |
| SCHEMBL12415767 | 0.70 | ENPP1 (0.38) | PTGDR2POLBNOS1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1718649-A2 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | Actimis Pharmaceuticals, Inc., (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005073234-A2 | IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | HRH2, CCR2, HRH1 | PTGDR2 56/4885CYP1A2 1867/4885POLB 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.